Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial-Reference-Cited by-同舟云学术

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial

Published:2015-03-30 Issue:1 Volume:170 Page:29-39
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mead Adam J.¹,Milojkovic Dragana²,Knapper Steven³,Garg Mamta⁴,Chacko Joseph⁵,Farquharson Mira⁶,Yin John⁷,Ali Sahra⁸,Clark Richard E.⁹,Andrews Chris¹⁰,Dawson Meryem Ktiouet¹⁰,Harrison Claire¹¹

Affiliation:

1. MRC Weatherall Institute of Molecular Medicine; University of Oxford; Oxford UK

2. Imperial College Healthcare NHS Trust; Hammersmith Hospital; London UK

3. Department of Haematology; Cardiff University, Heath Park; Cardiff UK

4. Leicester Royal Infirmary; Leicester UK

5. The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust; Bournemouth UK

6. Department of Haematology; Western General Hospital; Edinburgh UK

7. Department of Haematology; Manchester Royal Infirmary; Manchester UK

8. Hull and East Yorkshire Hospitals NHS Trust; Hull UK

9. Department of Haematology; Royal Liverpool University Hospital; Liverpool UK

10. Novartis Pharmaceuticals UK; Frimley UK

11. Guy's and St. Thomas’ NHS Foundation Trust; London UK

Funder

Novartis

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13379/fullpdf

Reference32 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;Journal of the National Cancer Institute,1993

2. Primary myelofibrosis: update on definition, pathogenesis, and treatment;Abdel-Wahab;Annual Review of Medicine,2009

3. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

4. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire;Brazier;Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation,1993

5. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study;Cancer;2024-07-30

3. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

4. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices;Current Hematologic Malignancy Reports;2024-03-05

5. The interference between SARS-COV-2 and Alzheimer’s disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic;Ageing Research Reviews;2024-02